• 1
    Veronesi U, Banfi A, Salvadori B, Luini A, Saccozzi R, Zucali R, Marubini E, Del Vecchio M, Boracchi P, Marchini S, Merson M, Sacchini V, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 1990; 26: 66870.
  • 2
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. Twenty-year follow up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 122771.
  • 3
    Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, et al. A Randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 54653.
  • 4
    Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394401.
  • 5
    DiFronzo LA, Hansen NM, Stern SL, Brennan MB, Giuliano AE. Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer? Ann Surg Oncol 2000; 7: 40610.
  • 6
    Krag DN. The sentinel node for staging breast cancer: current review. Breast Cancer 1999; 6: 2336.
  • 7
    Jansen L, Nieweg OE, Valdes Olmos RA, Rutgers EJ, Peterse JL, de Vries J, Doting MH, Kroon BB. Improved staging of breast cancer through lymphatic mapping and sentinel node biopsy. Eur J Surg Oncol 1998; 24: 4456.
  • 8
    Veronesi U. The sentinel node and breast cancer. Br J Surg 1999; 86: 12.
  • 9
    Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A, Renne G, Pruneri G, Maisonneuve P, Veronesi U. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92: 137884.
  • 10
    Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Cassano E, De Cicco C, Intra M, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91: 36873.
  • 11
    Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998; 339: 9416.
  • 12
    Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18: 25539.
  • 13
    Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, Ng PC, Edwards MS, Halliday BE, Henry CA, Sommers LM, Carman CM, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001; 233: 519.
  • 14
    Noguchi M, Tsugawa K, Miwa K. Internal mammary chain sentinel lymph node identification in breast cancer. J Surg Oncol 2000; 73: 7580.
  • 15
    Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-Year results of a randomised trial. Eur J Cancer 1999; 35: 13205.
  • 16
    Le MG, Arriagada R, de Vathaire F, Dewar J, Fontaine F, Lacour J, Contesso G, Tubiana M. Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes? Cancer 1990; 66: 23138.
  • 17
    Lacour J, Le MG, Hill C, Kramar A, Contesso G, Sarrazin D. Is it useful to remove internal mammary nodes in operable breast cancer? Eur J Surg Oncol 1987; 13: 30914.
  • 18
    Cody HS,III, Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995; 2: 327.
  • 19
    Galimberti V, Veronesi P, Arnone P, De Cicco C, Renne G, Intra M, Zurrida S, Sacchini V, Gennari R, Vento A, Luini A, Veronesi U. Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol 2002; 9: 9248.
  • 20
    Dooley WC, Ljung BM, Veronesi U, Elledge R, Cazzaniga M, Elledge RM, O'Shaughnessy J, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001; 93: 162432.
  • 21
    Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982; 49: 7518.
  • 22
    O'Shaughnessy JA, Ljung BM, Dooley WC. Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer 2002; 94: 2928.
  • 23
    Helvie MA, Chang HP, Adler DD, Boyd PG. Breast thickness in routine mammograms: effect on image quality and radiation dose. Am J Roentgenol 1994; 163: 13714.
  • 24
    Benson SR, Blue J, Judd K, Harman JE. Ultrasound is now better than mammography for the detection of invasive breast cancer. Am J Surg 2004; 188: 3815.
  • 25
    Gordon PB, Goldenberg SL. Malignant breast masses detected only by ultrasound. A retrospective review. Cancer 1995; 76: 62630.
  • 26
    Kneeshaw PJ, Turnbull LW, Drew PJ. Current applications and future direction of MR mammography. Br J Cancer 2003; 88: 410.
  • 27
    Heywang-Kobrunner SH, Bick U, Bradley WG, Bone B, Casselman J, Coulthard A, Fischer U, Muller-Schimpfle M, Oellinger H, Patt R, Teubner J, Friedrich M, et al. International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 2001; 11: 53146.
  • 28
    Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22: 27785.
  • 29
    Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Zurrida S, Ivaldi G, Tosi G, Ciocca M, Tosoni A, De Lucia F. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 2001; 37: 217883.
  • 30
    Veronesi U, Gatti G, Luini A, Intra M, Ciocca M, Sanchez D, Zurrida S, Navarro S, Orecchia R. Full-dose intraoperative radiotherapy with electrons during breast conserving surgery. Arch Surg 2003; 138: 12536.
  • 31
    Reitsamer R, Peintinger F, Kopp M, Menzel C, Kogelnik HD, Sedlmayer F. Local recurrences rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study. Strahlenther Onkol 2004; 180: 3844.
  • 32
    Vaidya JS, Baum M, Tobias JS, D'Souza DP, Naidu SV, Morgan S, Metaxas M, Harte KJ, Sliski AP, Thomson E. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 2001; 12: 107580.
  • 33
    Luini A, Zurrida S, Paganelli G, Galimberti V, Sacchini V, Monti S, Veronesi P, Viale G, Veronesi U. Comparison of radioguided excision with wire localization of occult breast lesions. Br J Surg 1999; 86: 5225.
  • 34
    Galimberti V, Zurrida S, Zanini V, Callegari M, Veronesi P, Catania S, Luini A, Greco M, Grisotti A. Central small size breast cancer: how to overcome the problem of nipple and areola involvement. Eur J Cancer 1993; 29: 10936.
  • 35
    Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 66228.
  • 36
    Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer 2006;( Suppl 2): S36S40. Review.
  • 37
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 10819.
  • 38
    Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 93938.
  • 39
    Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 23436.
  • 40
    Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, Luini A, Andreola S, Rilke F, Raselli R, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222: 6128.
  • 41
    Zurrida S, Greco M, Veronesi U. Surgical pitfalls after preoperative chemotherapy in large size breast cancer. Eur J Surg Oncol 1994; 20: 6413.
  • 42
    Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 336.
  • 43
    Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 12737.
  • 44
    Fisher B, Costantino JP, Wickerham DL, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 137188.
  • 45
    Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17: 106571.
  • 46
    Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 937.
  • 47
    Fisher B, Costantino JP, Wickerham DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 137188.
  • 48
    Decensi A, Robertson C, Viale G. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003; 95: 77990.
  • 49
    Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G, Veronesi U. Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 2002; 9: 26671.